Biochemistry & Molecular Biology Letters

Review | Vol 3 Iss 2

Effect of P-glycoprotein Mediated Inhibition in Drug Bioavailability

Nikhila Vengala*
Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India

*
Corresponding author: Nikhila Vengala, M. Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth Deemed
University, Pune, Maharashtra, India, E-mail: nikhilavengala25@gmail.com

Received: February 08, 2017; Accepted: March 16, 2017; Published: March 23, 2017

Abstract
P-glycoprotein (P-gp) is a multispecific transporter which has a herbal detoxification feature. The inhibition of substrate delivery by
way of P-gp can be provided through a number of parameters. P-glycoprotein (P-gp), an efflux membrane transporter, is extensively
distributed at some stage in the body and is answerable for limiting mobile uptake and the distribution of xenobiotics and toxic
materials. Inhibition steady is thought to be an extra massive parameter permitting smooth assessment of statistics from wonderful
substrate conditions. Because of its importance in pharmacokinetics, P-glycoprotein shipping screening has been incorporated into the
drug discovery procedure. P-glycoprotein (P-gp), an efflux transporter expressed in tumour and regular tissues, may also additionally
appreciably affect pharmacodynamics and pharmacokinetics of the drug, compromising its pharmacological effect. Multidrug
resistance (MDR) takes place due to cellular expression of P-gp in vitro and is assumed to be a clinically applicable mechanism for
tumour resistance to chemotherapy.

Keywords: P-glycoprotein, Multidrug resistance, ATP binding cassette, P-gp inhibitors, Bioavailability

Introduction
P-glycoprotein (P-gp) is a trans layer penetrability glycoprotein having a place with the ATP binding cassette (ABC)
extraordinary family that abilities particularly as a supplier intervened essential fiery efflux transporter[1-4]. It is broadly
distributed all through the body and has a different scope of substrates that incorporate various fundamental recuperating
retailers whose bioavailability is diminished or resistance is created as a result of the protein efflux. P-gp turn out to be
initially decided in 1976 for its capacity in multi-sedate resistance in many diseases; it's far over communicated in a few
human tumors and is a pivotal hindrance to accomplishment in many malignancies cure. Because of its part in medication
digestion, P-gp has far reaching clinical importance as it impacts the ingestion, appropriation and discharge of anticancer
pills. A few regular items from verdure and marine assets had been accounted for his or her P-gp inhibitory development and
along these lines filling in as limit chemo preventives when co-controlled with hostile to malignancy operators. A few
flavonoids had been articulated to manifest P-gp hindrance[5-8]. These P-gp inhibitors from common assets may also go
about as limit enhancers of bioavailability of various anticancer containers by utilizing keeping the multi-medicate resistance,
diminishing the intense measurement of anticancer pills and their related reactions.

Citation: Vengala N. Antioxidant Effect of P-glycoprotein Mediated Inhibition in Drug Bioavailability. Biochem Mol Biol Lett. 2017;
3(2):124.
© 2017 Trade Science Inc.
1
www.tsijournals.com | June-2017

One of the most important defense mechanisms of ectoparasites in opposition to chemotherapeutic or xenobiotic
dealers is associated with the ATP binding cassette (ABC) transporter own family. The ABC transporters were related to
multidrug resistance (MDR) in one of a kind organisms. ABC proteins are able to recognize distinctive chemical substrates
and to govern their delivery on a mobile stage. Through this, the ABC proteins have a pivotal role in blocking off excessive
concentrations neurotoxins, which intend to go into the worried gadget of parasitic invertebrates. P-gp is a surprisingly
conserved membrane sure protein in eukaryotes and prokaryotes, and it features as an ATP-structured efflux pump, reducing
the attention of drugs within the cells and conferring resistance. In mammals, P-gp has been stated as one of the fundamental
boundaries towards the doorway of medication from the blood flow into the nervous system [9-14].
In order to promote awareness among the people, physicians and research experts unite to form a society or an
organization. The main aim of these societies is to counsel and bring awareness among the people suffering from cardiac
disorders and cancer and also among healthy personnel [15-25]. ACRO India is one of the independent, non-profit
organization which promotes the quality of research related to bioequivalence studies. The Nigerian Society of Biochemistry
and Molecular Biology encourages researchers within the discipline of biochemistry and molecular biology to engage in huge
research that ends in pleasurable results.
Open Access literature provides a source for the information and current researches worldwide. Clinical
Pharmacology and Biopharmaceutics, an open access journal is informative regarding the science and technology of
pharmacology and bio pharmaceutics. It deals with the study of chemical and physical properties of pharmaceuticals, their
components and their activities in living organisms. Conferences like 3rd World Congress on Pharmacology August 08-10,
2016 Birmingham, UK, a presentation by Zeting Yuan on “Reversal of P-glycoprotein-mediated multidrug resistance by
Cinobufagin” explains about P-gp mediated multidrug resistance. Editor Abdelwahab Omri obtained his PhD from
University of Montréal whose key research interest is on effect of P-glycoprotein mediated MDR in liposomal drug delivery
system[26-32].
Journal of Bioequivalence & Bioavailability is a scholarly journal that encompasses a wide range of current research
on FDA Bioequivalence, Bioequivalence antipsychotics, Bioequivalence anticancer, Bioequivalence antidiuretics,
Bioequivalence antipsychotics, bioavailability and bioequivalence Studies, Biosimilars, Advances in Bioavailability and
offers a promising platform for the authors to make their valuable contributions towards the journal. These journals provides
information through online open access and thereby helps in improving the citations for authors and attaining good journal
impact factors [33,34].

P-GP and multidrug resistance

The failure of cancer remedy can be attributed to a variety of various pharmacological and scientific reasons;
however one important cause of the remedy failure is Multidrug Resistance (MDR) to chemotherapeutics. MDR mechanisms
can bring about resistance to a number of structurally and functionally unrelated chemotherapeutic agents[35-43]. The MDR
behavior is mainly related to the interest of trans membrane efflux pumps inclusive of P-glycoprotein 1 (P-gp/ABCB1),
breast cancers resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 1 (MRP1/ABCC1), which are
members of ATP-Binding Cassette transporter own family. P-gp, also known as multidrug resistance protein 1 (MDR1), is a
nicely-studied glycoprotein that established its function as a transporter of hydrophobic pills, lipids, steroids and metabolic
merchandise[44-56].
Apart from its role in multidrug resistance, P-gp has a profound function in pharmacokinetics, affecting drug
absorption, distribution and excretion. It is observed in high amounts on the apical surface of epithelial cells lining the colon
and small gut and in hepatocytes, pancreas ductules [57-60], proximal tubules in kidneys and the adrenal gland[61,62]. P-gp

2
www.tsijournals.com | June-2017

is also recognized to play a main role in transporting compounds out of the brain in the blood brain barrier. Within the BBB,
most effective certainly lipophilic compounds can diffuse throughout the endothelial cells and input the brain. But, an
excessive share of P-gp that surrounds this place of the brain prevents their accumulation by means of distributing substrates
returned into the blood circulate [63-69]. Inside the gastrointestinal tract and in hepatocytes, P-gp is chargeable for the efflux
of medication again into lumen/bile, therefore lowering the bioavailability of substrate pills. Further, in kidneys, P-gp is
placed more often than not in glomerular mesangium cells and the apical membrane of proximal tubule epithelia and plays a
good sized function within the tubular secretion of organic cations [70-78].
P-glycoprotein mediated inhibition
The clinical relevance of P-gp no longer best in multi-drug resistance to cancer and CNS sicknesses but additionally
inside the modification of the pharmacokinetics of many tablets has sparked enormous hobby in the development of P-gp
modulators so as to conquer P-gp mediated efflux delivery [79-102]. The recognition that P-gp is responsible for multi-drug
resistance in most cancers and different illnesses led to applications accomplished for the invention and improvement of P-gp
inhibitors in order to triumph over that functional barrier and permit drug penetration into the target tissue.
Three generations of P-gp inhibitors had been advanced over the past many years. The first-generation of P-gp
inhibitors had been determined by means of investigating capsules already used in clinical practice that correctly blocked the
function of P-gp In vitro and protected verapamil, cyclosporine A, anti-estrogens and anti-hypertensive analogues of quinine.
But, due to their low and non-selective affinity for P-gp [103-115], excessive doses of those first-generation inhibitors were
had to inhibit P-gp In vivo ensuing in clinically considerable toxicity profiles An on-going and relentless search to discover
more effective and safe P-gp inhibitors stays these days no longer best for improving cancer and important apprehensive
gadget -diseases remedy however also to improve the pharmacokinetic houses of several drugs [116-125]. The expertise that
P-gp is strongly involved in drug kinetics caused the recognition of essential scientific drug-drug interactions with
consequent impact at the disposition, dosing routine, efficacy and safety of diverse drugs and herbal dietary supplements
[126-143].
Conclusion
P-gp over-expression has been discovered in numerous diseases inflicting MDR to chemotherapeutics used for the
treatment of tumors and CNS diseases because of the active shipping of the drugs out of the cells. Moreover, P-gp has also
been proven to be an critical drug efflux transporter in intestine, liver, kidney, brain and other epithelial tissues. It is
consequently documented to compromise the improvement of latest capsules with obvious successful pharmacokinetic traits
and to be concerned in pharmacokinetic clinically enormous drug interactions [144,145]. Since presently P-gp is one of the
most nicely understood drug efflux transporters with recognize to its regulation, tissue expression, substrate specificity and
modulation of its function, it's miles critical to assess the ability of a compound to interact with P-gp.
References
1. Sharifi M, Raevsky AV, Ghafourian T. Effect of Molecular Structure, Substrate and Docking Scores on the
Prediction of the Inhibition Constants of P-glycoprotein Inhibitors. J Drug Metab Toxicol. 2016; 7:217.
2. Gupta P. P-Glycoprotein Inhibitors from Natural Sources as Chemopreventives. Nat Prod Chem Res. 2016; 4:e116.
3. Naruhashi K, Kamino A, Ochi E, et al. Transport Mechanism of Intestinal Absorption of μ Opioid Receptor
Agonists and Contribution of P-Glycoprotein in Rats and Human Intestinal Epithelial Caco-2. Clin Pharmacol
Biopharm. 2016; 5:154.

3
www.tsijournals.com | June-2017

4. Bedada SK, Yakkanti SA, Neerati P. Resveratrol Enhances the Bioavailability of Fexofenadine in Healthy Human
Male Volunteers: Involvement of P-Glycoprotein Inhibition. J Bioequiv Availab. 2014; 6:158-163.
5. Valenzuela-Muñoz V, Nuñez-Acuña G, Gallardo-Escárate C. Molecular Characterization and Transcription
Analysis of P-Glycoprotein Gene from the Salmon Louse Caligus rogercresseyi. J Aquac Res Development. 2014;
5:236.
6. Neerati P, Sudhakar YA, Kanwar JR. Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in In-situ
Cancerous Colon Perfusion Rat Model. J Cancer Sci Ther. 2013; 5:313-319.
7. Fortuna A, Alves G, Falcão A. In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug
Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol. J Bioequiv Availab. 2011; S2.
8. Karthikeyan R, Mohamed S, Sridhar V, et al. Support Vector Machine Classifier for Predicting Drug Binding to P-
glycoprotein. J Proteomics Bioinform. 2009; 2: 193-201.
9. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and
the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000; 11:
265-283.
10. Malmo J, Sandvig A, Varum KM, et al. Nanoparticle mediated P-glycoprotein silencing for improved drug delivery
across the blood-brain barrier: a siRNA-chitosan approach. PLoS One. 2013; 8: e54182.
11. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug
transporter. Annu Rev Pharmacol Toxicol. 1999; 39: 361-398.
12. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci. 1992; 17: 18-21.
13. Aller S, Yu J,Ward A, et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding.
Science. 2009; 323: 1718-1722.
14. Lu L, Leonessa F, Clarke R, et al. Competitive and allosteric interactions in ligand binding to P-glycoprotein as
observed on an immobilized P-glycoprotein liquid chromatographic stationary phase. Mol Pharmacol. 2001; 59: 62-
68.
15. Martin C, Berridge G, Higgins CF, et al. Communication between multiple drug binding sites on P-glycoprotein.
Mol Pharmacol. 2000; 58: 624-632.
16. Maki N, Moitra K, Ghosh P, et al. Allosteric modulation of the human P-glycoprotein involves conformational
changes mimicking catalytic transition intermediates. J Biol Chem. 2006; 281: 10769-10777.
17. Ekins S, Kim RB, Leake BF, et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-
glycoprotein. Mol Pharmacol. 2002; 61: 964-973.
18. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which
causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22: 3099-3108.
19. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the
distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000; 28: 655-660.
20. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Potent
Cyclopropyldibenzosuberane Modulator, LY335979. Cancer Res. 1996; 56: 4171-4179.
21. Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro
and pharmacoepidemiological studies. Clin Pharmacokinet. 2007; 46: 1039-1049.

4
www.tsijournals.com | June-2017

22. Ekins S, Kim RB, Leake BF, et al. Application of three-dimensional quantitative structure-activity relationships of
P-glycoprotein inhibitors and substrates. Mol Pharmacol. 2002; 61: 974-981.
23. Eriksson UG, Dorani H, Karlsson J, et al. Influence of erythromycin on the pharmacokinetics of ximelagatran may
involve inhibition of P-glycoprotein-mediated excretion. Drug Metab Dispos. 2006; 34: 775-782.
24. Kakumoto M, Takara K, Sakaeda T, et al. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal
drugs. Biol Pharm Bull. 2002; 25: 1604-1607.
25. Katoh M, Nakajima M, Yamazaki H, et al. Inhibitory effects of CYP3A4 substrates and their metabolites on P-
glycoprotein-mediated transport. Eur J Pharm Sci. 2001; 12: 505-513.
26. Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical
drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci. 2006; 27: 543-554.
27. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain
penetration and pharmacological activity of many drugs. J Clin Invest. 1996; 97: 2517-2524.
28. Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin
Pharmacol Ther. 2000; 68: 231-237.
29. Wandel C, Kim R, Wood M, et al. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the
efflux drug transporter P-glycoprotein. Anesthesiology. 2002; 96: 913-920.
30. Zhang Y, Guo X, Lin ET, et al. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a
novel cysteine protease inhibitor. Drug Metab Dispos. 1998; 26: 360-366.
31. Taipalensuu J, Tornblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the
ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell
monolayers.J Pharmacol ExpTher. 2001; 299: 164-170.
32. Quan F, Pan C, Ma Q, et al. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed
Pharmacother. 2008; 62: 622-629.
33. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability:
possible role of organic anion transporting polypeptides. Clin Pharmacol Ther. 2005; 77: 170–177.
34. Yamada S, Yasui-Furukori N, Akamine Y, et al. Effects of the P-glycoprotein inducer carbamazepine on
fexofenadine pharmacokinetics. Ther Drug Monit. 2009; 31: 764-768.
35. Shimizu M, Uno T, Sugawara K, et al. Effects of itraconazole and diltiazem on the pharmacokinetics of
fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol. 2006; 61: 538-544.
36. Uno T, Shimizu M, Sugawara K, et al. Lack of dose dependent effects of itraconazole on the pharmacokinetic
interaction with fexofenadine. Drug Metab Dispos. 2006; 34: 1875–1879.
37. Pohl P, Klafke G, Júnior JR, et al. ABC Transporters as a Multidrug Detoxification Mechanism in Rhipicephalus
(Boophilus) Microplus. Parasitol Res. 2012; 111: 2345-2351.
38. Juranka PF, Zastawny RL, Ling V. P-Glycoprotein: Multidrug-Resistance and a Superfamily of Membrane-
Associated Transport Proteins. FASEB J. 1989; 3: 2583-2592.
39. Pouliot Jf, L'Heureux F, Liu Z, et al. Reversal of P-Glycoprotein-Associated Multidrug Resistance by Ivermectin.
Biochem Pharmacol. 1997; 53: 17-25.
40. Xu M, Molento M, Blackhall W, et al. Ivermectin Resistance in Nematodes May Be Caused by Alteration of P-
Glycoprotein Homolog. Mol Biochem Parasitol. 1998; 91: 327-335.

5
www.tsijournals.com | June-2017

41. Hung LW, Wang IX, Nikaido K, et al. Crystal Structure of the ATP-Binding Subunit of an ABC Transporter.
Nature. 1998; 396: 703-707.
42. Buss DS, Mccaffery AR, Callaghan A. Evidence for P-Glycoprotein Modification of Insecticide Toxicity in
Mosquitoes of the Culex Pipiens Complex. Med Vet Entomol. 2002; 16: 218-222.
43. Luckenbach T, Epel D. ABCB-And ABCC-Type Transporters Confer Multixenobiotic Resistance and Form an
Environment-Tissue Barrier In Bivalve Gills. Am J Physiol Regul Integr Comp Physiol. 2008; 294: R1919-R1929.
44. Bourguinat C, Ardelli BF, Pion Sbds, et al. P-Glycoprotein-Like Protein, A Possible Genetic Marker for Ivermectin
Resistance Selection in Onchocerca volvulus. Mol Biochem Parasitol. 2008; 158: 101-111.
45. Veau C, Faivre L, Tardivel S, et al. Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality
in mice. J Pharmacol Exp Ther. 2002; 302: 742-750.
46. Linn SC, Giaccone G. MDR1/P-glycoprotein expression in colorectal cancer. Eur J Cancer. 1995; 31A: 1291-1294.
47. Linardi RL, Natalini CC. Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and
pharmacodymanic of therapeutic drugs. Cienc Rural. 2006; 36: 336-341.
48. Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve
central nervous system pharmacotherapy. Pharmacol Rev. 2008; 60: 196-209.
49. Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the
correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12: 413-420.
50. Bansal T, Mishra G, Jaggi M, et al. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and
pharmacokinetics of irinotecan in rats. Eur J Pharm Sci. 2009; 36: 580-590.
51. Lü Y, Yan Y, Wang XF. Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in
astrocytes cultured from rat brains. Chin Med J (Engl). 2004; 117: 1682-1686.
52. Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve
central nervous system pharmacotherapy. Pharmacol Rev. 2008; 60: 196-209.
53. Singh DV, Godbole MM, Misra K. A plausible explanation for enhanced bioavailability of P-gp substrates in
presence of piperine: simulation for next generation of P-gp inhibitors. J Mol Model. 2013; 19: 227-238.
54. Kanwar JR, Singh N, Kanwar RK. Role of nanomedicine in reversing drug resistance mediated by ATP binding
cassette transporters and P-glycoprotein in melanoma. Nanomedicine (Lond). 2011; 6: 701-714.
55. Shukla S, Zaher H, Hartz A, et al. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked
ABC drug transporter in mice. Pharm Res. 2009; 26: 480-487.
56. Angelini A, Iezzi M, Di Febbo C, et al. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma
MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep. 2008; 20: 731-735.
57. Ma JD, Tsunoda SM, Bertino JS Jr, et al. Evaluation of In vivo P-glycoprotein phenotyping probes: a need for
validation. Clin Pharmacokinet. 2010; 49: 223-237.
58. Marchetti S, Mazzanti R, Beijinen J, et al. Concise Review: Clinical Relevance of Drug–Drug and Herb–Drug
Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007; 12: 927-941.
59. Watkins P. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev. 1997; 27:
161-170.
60. Kivistö K, Niemi M, Fromm M. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin
Pharmacol. 2004; 18: 621-626.

6
www.tsijournals.com | June-2017

61. Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.
Biochim Biophys Acta. 1976; 455: 152-162.
62. Cascorbi I. P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations.
Handb Exp Pharmacol. 2011; 201: 261-283.
63. Nobili S, Landini I, Giglioni B, et al. Pharmacological Strategies for overcoming Multidrug Resistance. Curr Drug
Targets. 2006; 7: 861-879.
64. del Amo EM, Heikkinen AT, Mönkkönen J. In vitro-In vivo correlation in P-glycoprotein mediated transport in
intestinal absorption. Eur J Pharm Sci. 2009; 36: 200-211.
65. Linnet K, Ejsing T. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on
psychotropic drugs. Eur Neuropsychopharmacol. 2008; 18: 157-169.
66. Yamazaki M, Neway W, Ohe T, et al. In vitro substrate identification studies for p-glycoprotein-mediated transport:
species difference and predictability of In vivo results. J Pharmacol Exp Ther. 2001; 296: 723-35.
67. Tandon V, Kapoor B, Bano G, et al. P-glycoprotein: pharmacological relevance. Indian J Pharmacol. 2006; 38: 13-
24.
68. Bansal T, Jaggi M, Khar R, et al. Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer
Chemotherapy. J Pharm Pharm Sci. 2009; 12: 46-78.
69. Aller S, Ju J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poli-specific drug binding.
Science. 2009; 323: 1718- 1722.
70. Sauna Z, Ambudkar S. About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and
hydrolysis to do mechanical work. Mol Cancer Ther. 2007; 6: 13-23.
71. Varma M, Ashokraj Y, Dey C, et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability
enhancement. Pharmacol Res. 2003; 48: 347-359.
72. Fung K, Gottlesman M. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein
function. Biochem Biophys Acta. 2009; 1794: 860-871.
73. Elsinga P, Hendrikse N, Bart J, et al. PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it
Affects Uptake and Binding of Drugs within the CNS. Curr Pharm Des. 2004; 10: 1493-1506.
74. Thuerauf N, Fromm M. The role of the transporter P-glycoprotein for disposition and effects of centrally acting
drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci. 2006; 256: 281-286.
75. Goole J, Lindley D, Roth W, et al. The effects of excipients on transporter mediated absorption. Int J Pharm. 2010;
393: 17-31.
76. Choong E, Dobrinas M, Carrupt PA, et al. The permeability P-glycoprotein: a focus on enantioselectivity and brain
distribution. Expert Opinion Drug Metab Toxicol. 2010; 6: 953-965.
77. Miura M, Uno T, Tateishi T, et al. Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects. Chirality .
2007; 19: 223-227.
78. Nikisch G, Eap C, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped
depressive patients and clinical response: A pilot study. Pharmacol Res. 2008; 58: 344-347.
79. Sakugawa T, Miura M, Hokama N, et al. Enantioselective disposition of fexofenadine with the P-glycoprotein
inhibitor verapamil. Br J Clin Pharmacol. 2009; 67: 535-540.

7
www.tsijournals.com | June-2017

80. McDevitt C, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors?
Pharmacol Therap. 2007; 113: 429-441.
81. Vaalburg W, Hendrikse N, Elsinga P, et al. P-glycoprotein activity and biological response. Toxicol Appl
Pharmacol. 2005; 207: S257-S260.
82. Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J
Clin Pathol. 2002; 55: 332-339.
83. Bebawy M, Sze DM . Targeting P-glycoprotein for Effective Oral Anti- Cancer Chemotherapeutics Curr Cancer
Drug Targets. 2008; 8: 47-52.
84. van Kalken C, Giaccone G, van der Valk P, et al. Multidrug resistance gene (P-glycoprotein) expression in the
human fetus. Am J Pathol. 1992; 141: 1063-1072.
85. Huls M, Russel F, Masereeuw R. The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ
Regeneration. J Pharmacol Exp Ther. 2009; 328: 3-9.
86. Canaparo R, Finnström N, Serpe L, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach,
jejunum and ileum. Clin Exp Pharmacol Physiol. 2007; 34: 1138-1144.
87. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;
42: 59-98.
88. Zhang Y, Benet L. The gut as a barrier to drug absorption: combined role of cytochrome P4503A and P-
glycoprotein. Clin Pharmacokinet. 2001; 40: 159-168.
89. Waterbeemd H, Gifford E. Admet in Silico Modelling: Towards Prediction Paradise? Nat Rev Drug Discov. 2003;
2: 192-204.
90. Waterbeemd H, Smith D, Beaumont K, et al. Property-Based Design: Optimization of Drug Absorption and
Pharmacokinetics. J Med Chem. 2001; 44: 1313-1333.
91. Shugarts S, Benet L. The role of transporters in pharmacokinetics of orally administered drugs. Pharm Res. 2009;
26: 2039-2054.
92. Tellingen O. The importance of drug-transporting P-glycoproteins in toxicology. Toxicol Lett. 2001; 120: 31-41.
93. Löscher W, Potschka H. Blood-Brain Barrier Active Efflux Transporters: ATP-Binding Cassette Gene Family.
NeuroRx. 2005; 2: 86-98.
94. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain
diseases. Prog Neurobiol. 2005; 76: 22-76.
95. Miller D. Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier. Trends
Pharmacol Sci. 2010; 31: 246-254.
96. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: A novel therapeutic approach.
Pharmacol Ther. 2010; 125: 118-127.
97. Urquhart B, Kim R. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol. 2009;
65: 1063-1070.
98. Kwan P, Arzimanoglou A, Berg A, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc
Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51: 1069- 1077.
99. Schmidt D, Löscher W. Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms. Epilepsia.
2005; 46: 858-877.

8
www.tsijournals.com | June-2017

100. von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small
intestinal enterocytes and hepatocytes: a comparativeanalysis in paired tissue specimens. Clin Pharmacol Ther.
2004; 75: 172-183.
101. Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts.
Pharm Res. 2004; 21: 719-735.
102. Faber KN, Müller M, Jansen PL. Drug transport proteins in the liver. Adv Drug Deliv Rev. 2003; 55: 107-124.
103. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug
absorption and bioavailability. Eur J Pharm Sci. 2004; 21: 25-51.
104. Kusuhara H, Sugiyama Y. In vitro-In vivo extrapolation of transportermediated clearance in the liver and kidney.
Drug Metab Pharmacokinet. 2009; 24: 37-52.
105. Perri D, Ito S, Rowsell V, Shear NH. The kidney--the body’s playground for drugs: an overview of renal drug
handling with selected clinical correlates. Can J Clin Pharmacol. 2003; 10: 17-23.
106. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev. 2003;
55: 53-81.
107. Taylor E. The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders. Clin
Pharmacokinet. 2002; 41: 81-92.
108. Abraham J, Edgerly M, Wilson R, et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination
with vinorelbine. Clin Cancer Res. 2009; 15: 3574-3582.
109. Colabufo NA, Contino M, Berardi F, et al. A new generation of MDR modulating agents with dual activity: P-gp
inhibitor and iNOS inducer agents. Toxicol In vitro. 2011; 25: 222-230.
110. Eng KT, Berdis AJ. A novel non-natural nucleoside that influences P-glycoprotein activity and mediates drug
resistance. Biochemistry. 2010; 49: 1640- 1648.
111. Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther.
2007; 7: 447-459.
112. Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144-093, a novel inhibitor of
P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000; 60: 2964-2972.
113. Holtzman C, Wiggins B, Spinler S. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy. 2006; 26:
1601-1607.
114. International Transporter Consortium . Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9:
215-236.
115. Huang B, Li G, Luo J, et al. Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery
using chitosan capsule as a carrier. World J Gastroenterol. 2008; 14: 4928-4937.
116. Zhang J, Zhang Y, Zhao P, et al. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009; 11: 300-
306.
117. Zhang L, Reynolds K, Zhao P, et al. Drug interactions evaluation: An integrated part of risk assessment of
therapeutics. Toxicol Appl Pharmacol. 2010; 243: 134-145.
118. Hughes J, Rees S, Kalindjian S, et al. Principles of early drug discovery. Br J Pharmacol. 2011; 162: 1239-1249.
119. Yengi L, Leung L, Kao J. The Evolving Role of Drug Metabolism in Drug Discovery and Development. Pharm Res.
2007; 24: 842-858.

9
www.tsijournals.com | June-2017

120. Schwab D, Fischer H, Tabatabaei A, et al. Comparison of in vitro P-glycoprotein screening assays:
recommendations for their use in drug discovery. J Med Chem. 2003; 46: 1716-1725.
121. Hochman J, Yamazaki M, Ohe T, et al. Evaluation of Drug Interactions with P-Glycoprotein in Drug Discovery: In
vitro Assessment of the Potential for Drug-Drug Interactions with P-Glycoprotein. Curr Drug Metab. 2002; 3: 257-
273.
122. Zhang Y, Bachmeier C, Miller DW. In vitro and In vivo models for assessing drug efflux transporter activity. Adv
Drug Deliv Rev. 2003; 55: 31-51.
123. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of In vitro and In vivo drug-drug interaction studies: a
Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003; 31: 815-
832.
124. Keogh JP, Kunta JR. Development, validation and utility of an In vitro technique for assessment of potential clinical
drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci. 2006; 27: 543-554.
125. Shaik N, Giri N, Pan G, et al. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits
cellular accumulation and brain distribution. Drug Metab Dispos. 2007; 35: 2076-2085.
126. Tang F, Horie K, Borchardt RT. Are MDCK cells transfected with the human MDR1 gene a good model of the
human intestinal mucosa? Pharm Res. 2002; 19: 765-772.
127. Wandel C, Kim RB, Kajiji S, et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory
potencies. Cancer Res. 1999; 59: 3944-3948.
128. Wang E, Casciano CN, Clement RP, et al. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor
of MDR1 product P-glycoprotein. Cancer Res. 2001; 61: 7525-7529.
129. Ghafourian T, Barzegar-Jalali M, Dastmalchi S, et al. QSPR models for the prediction of apparent volume of
distribution. International journal of pharmaceutics. 2006; 319: 82-97.
130. Löschmann N, Michaelis M, Rothweiler F, et al. Testing of SNS-032 in a panel of human neuroblastoma cell lines
with acquired resistance to a broad range of drugs. Transl Oncol. 2013; 6: 685-696.
131. Dolghih E, Bryant C, Renslo AR, et al. Predicting Binding to P-Glycoprotein by Flexible Receptor Docking. PLoS
Comput Biol. 2011; 7: e1002083.
132. Michaelis M, Rothweiler F, Nerreter T, et al. Differential Effects of the Oncogenic BRAF Inhibitor PLX4032
(Vemurafenib) and its Progenitor PLX4720 on ABCB1 Function. J Pharm Pharm Sci. 2014; 17: 154-168.
133. Hill T, Lewicki P. STATISTICS methods and applications. A comprehensive reference for science, industry and
data mining, StatSoft Inc. 2006; Tulsa, USA.
134. Kass GV. An Exploratory Technique for Investigating Large Quantities of Categorical Data. Applied Statistics.
1980; 29: 119-127.
135. Breiman L. Random forests. Machine learning. 2001; 45: 5-32.
136. Friedman JH. Multivariate Adaptive Regression Splines. The Annals of Statistics. 1991; 19: 1-67.
137. Wildman SA, Crippen GM. Prediction of Physicochemical Parameters by Atomic Contributions. J Chem Inf
Comput Sci. 1999; 39: 868-873.
138. Wang RB, Kuo CL, Lien LL, et al. Structure-activity relationship: analyses of p-glycoprotein substrates and
inhibitors. J Clin Pharm Ther. 2003; 28: 203-228.

10
www.tsijournals.com | June-2017

139. Hawkins PC, Skillman AG, Nicholls A. Comparison of shape-matching and docking as virtual screening tools. J
Med Chem. 2007; 50: 74-82.
140. Schulz-Gasch T, Stahl M. Scoring functions for protein–ligand interactions: a critical perspective. Drug Discovery
Today: Technologies. 2004; Elsevier.
141. Lipkowitz KB, Boyd DB. Reviews in computational chemistry, 2002; Vol 18, Wiley-VCH, New York.
142. Davis AM, Teague SJ. Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis.
Teague, Angew. Chem Int Ed. 1999; 38: 736-749.
143. Teague SJ. Implications of protein flexibility for drug discovery. Nature Reviews: Drug Discovery. 2003; 2: 527-
541.
144. Loo TW, Bartlett MC, Clarke DM. Substrate-induced conformational changes in the transmembrane segments of
human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J biol chem. 2003;
278: 13603-13606.
145. Loo TW, Bartlett MC, Clarke DM. Identification of Residues in the Drug Translocation Pathway of the Human
Multidrug Resistance P-glycoprotein by Arginine Mutagenesis. J of biol chem. 2009; 284: 24074-24087.

11